//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
ProfileReplies









Loading...
Still waiting in Mexico 🇲🇽😔 #nephjc #nephsky #medsky
1mo
9/10 I want more info: Blog by @sayalibthakare.bsky.social @drsaivani.bsky.social www.nephjc.com/news/trcpc6inhibition-fsgs VA by Dr. Divya Bajpai www.nephjc.com/news/2026/5/3/trpc6-inhibition-the-visual-abstract
#TenPostNephJC #NephSky #NephJC 1/10 How often do we miss non-diabetic kidney disease (NDKD)? 🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash @glombandit.bsky.social kidney-international.org/article/S008...
✨Exciting news #NephtSky The new #NephJC editorial interns are here! 📢Give them a follow and make them feel at home 👉 @drbarbateba.bsky.social @ancast13.bsky.social @kiddokidney.bsky.social @andrewdelaat.bsky.social @farahwehbe92.bsky.social 👇👇 www.nephjc.com/news/2025/6/...
10/10 Final thoughts New drug, more data= good. Keep an eye out for data manipulation & always be a little skeptical. ➡️Up next May 19, 2026: Multifaceted Strategies for Hypertension Control in Low-Income Patients (Mills et al, NEJM, 2026) Join us www.nephjc.com/ How we doing?
Hypertension control remains stubbornly low in underserved communities. IMPACTS‑BP asks whether a team‑based, multi‑component approach can meaningfully improve BP control and adherence in low‑income patients 🎨 #VisualAbstract by @nephromommy-akshu.bsky.social www.nephjc.com/news/2026/5/...
1mo
7/10 Questions 2 #NephJC #Nephsky There was a lot of statistical manipulation and commentary on subgroups… Does this concern you in a small phase 2 trial? Are you aware of the concerns about data manipulation with Avacopan in phase 3 trials?
10/10 Final thoughts: ✈️🚉🚗 we made it to #ERA26, sorry we're a little late on the posts! @nephroseeker.medsky.social Renal biopsy in diabetics is still a gold standard to rule out NDKD and improve the survival in diabetic patients… Up next, LBCT from #ERA26 Join us at nephjc.com
8/10 #NephJC Consensus 1️⃣BI 764198 administration in 1° FSGS caused a modest ⬇️UPCR 2️⃣Unclear if this will lead to better eGFR outcomes in a heterogenous group of FSGS pts 3️⃣Appears most helpful in genetic FSGS with TRPC6 mutations
1mo
15d
9d
25d
1mo
9d
1mo
Need that coffee cup 🥰 #nephjc #nephsky #medsky
Nephrology Journal Club
Nephrology Journal Club
Nephrology Journal Club
Nephrology Journal Club
Nephrology Journal Club
Nephrology Journal Club
Nephrology Journal Club
1mo
Nephrology Journal Club
Milagros Flores
Milagros Flores